Haleon plc (NYSE:HLN) Shares Sold by Capital Fund Management S.A.

Capital Fund Management S.A. cut its stake in shares of Haleon plc (NYSE:HLN) by 75.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 54,421 shares of the company’s stock after selling 168,779 shares during the period. Capital Fund Management S.A.’s holdings in Haleon were worth $519,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Procyon Advisors LLC increased its holdings in Haleon by 41.3% in the 4th quarter. Procyon Advisors LLC now owns 230,240 shares of the company’s stock valued at $2,196,000 after purchasing an additional 67,329 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Haleon by 1,689.4% in the third quarter. Jane Street Group LLC now owns 264,977 shares of the company’s stock valued at $2,803,000 after buying an additional 250,169 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Haleon by 29.8% in the fourth quarter. Bank of New York Mellon Corp now owns 2,071,017 shares of the company’s stock valued at $19,758,000 after buying an additional 475,934 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Haleon by 25.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock valued at $53,791,000 after buying an additional 1,026,939 shares during the period. Finally, SeaCrest Wealth Management LLC purchased a new position in Haleon during the 4th quarter valued at about $102,000. 6.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on HLN. Sanford C. Bernstein lowered shares of Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. HSBC reissued a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Hsbc Global Res lowered Haleon from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Morgan Stanley cut Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Haleon in a research report on Monday, March 3rd. Six equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $10.95.

Haleon Price Performance

Shares of HLN opened at $10.17 on Thursday. The firm has a market capitalization of $45.95 billion, a price-to-earnings ratio of 29.91, a PEG ratio of 2.82 and a beta of 0.24. The firm’s fifty day simple moving average is $10.07 and its 200-day simple moving average is $9.81. Haleon plc has a twelve month low of $8.04 and a twelve month high of $10.80. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

Haleon (NYSE:HLN) last posted its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. The company had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. Equities analysts forecast that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The firm also recently announced a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be paid a dividend of $0.1166 per share. This is a boost from Haleon’s previous — dividend of $0.05. The ex-dividend date is Friday, April 25th. This represents a yield of 1.6%. Haleon’s payout ratio is presently 58.97%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.